Ventilator-associated pneumonia (VAP) continues to be a leading cause of morbidity and mortality in the nosocomial setting. For those patients who acquire VAP, the likelihood of dying is twice as high as that observed in ventilated patients without VAP, with mortality rates ranging from 33 to 50% 1,2 . To date, few scoring systems have been developed and validated to assess mortality risk in patients with VAP 3 . The Acute Physiology and Chronic Health Evaluation (APACHE) II score is the most widely utilised score to assess risk of death in intensive care units and is often used in many clinical trials to stratify severity of illness, including studies in patients with VAP [4] [5] [6] . However, the APACHE II score can be cumbersome to calculate and simpler, accurate scoring systems are still needed for the practising clinician. More recently, the new IBMP-10 score (Immunodeficiency, Blood pressure, Multilobar infiltrates, Platelet count, and 10-day hospitalisation) was found to be comparable to APACHE II in its ability to predict mortality for patients with VAP 7 .
The PIRO (Predisposition, Insult, Response, Organ dysfunction) is a scoring concept introduced in 2003 to predict mortality among patients with sepsis 8 . Most recently it has been adapted for VAP and community-acquired pneumonia 9, 10 . Lisboa and colleagues defined the VAP PIRO score based on four variables: presence of co-morbidities (chronic obstructive pulmonary disease, immunocompromised, heart failure, cirrhosis or chronic renal failure), bacteraemia, hypotension (systolic blood pressure <90 mmHg) and acute respiratory distress syndrome 9 . One point is given for each variable present; the resultant score is the sum of these four variables. Moreover, the VAP PIRO score demonstrated better performance than the APACHE II in predicting mortality at end of intensive care unit (ICU) stay. As the PIRO score SUMMARY The ventilator-associated pneumonia (VAP) PIRO score is a new scoring system based on the PIRO concept. The aim of this study was to validate the PIRO score against the Acute Physiology and Chronic Health Evaluation (APACHE) II and VAP APACHE II in an independent group of VAP patients. Areas under the receiver operating characteristic curves were compared to determine the tests' abilities to predict intensive care unit and 28-day mortality. Variables associated with intensive care unit mortality were evaluated. One hundred and forty-eight intensive care unit patients who met radiographic and clinical criteria for VAP were included. The area under the receiver operating characteristic curves for predicting intensive care unit mortality with the PIRO, APACHE II and VAP APACHE II scores were 0.605 (P=0.03), 0.631 (P=0.01) and 0.724 (P <0.0001), respectively. Areas under the receiver operating characteristic curve for predicting 28-day mortality were 0.614 (P=0.01) for PIRO, 0.633 (P=0.01) for APACHE II and 0.697 (P=0.002) for VAP APACHE II. No differences in area under the receiver operating characteristic curve between scores were found at either endpoint. Variables independently associated with intensive care unit mortality were bacteraemia (adjusted odds ratio 7.16, 95% confidence interval 1.19 to 42.98, P=0.03) and APACHE II (1.06, 1.01 to 1.11, P=0.006). VAP PIRO score was not a good predictor of intensive care unit and 28-day mortality. The low sensitivity and specificity of VAP PIRO score preclude its use clinically. has only been validated by the original population used to derive the score criteria, the aim of this study was to validate the performance of the PIRO score for predicting ICU and 28-day mortality against APACHE II score (collected on the day of ICU admission) and VAP APACHE II score (collected on the day of VAP diagnosis) in an independent group of VAP patients.
METHODS
We conducted a secondary analysis of data gathered from a previous study with 168 patients who developed VAP between July 2004 and August 2007 at our institution, Hartford Hospital, an 867-bed tertiary care medical centre located in Hartford, Connecticut, USA. The original study was a prospective, observational analysis of VAP patients who were initiated on an antibiotic clinical pathway and aimed to determine which antibiotic regimens would provide the greatest likelihood of a positive clinical response based on a pharmacodynamic modelling 11 . This study was approved by the Hartford Hospital Institutional Review Board and informed consent was waived because all data were already collected and the study was observational in nature.
Study patients
Patients enrolled were ≥17 years of age who developed VAP while admitted to one of the three ICUs (surgical, medical or neurotrauma) at our hospital. VAP was defined as an acute lower respiratory tract infection in a patient who had been mechanically ventilated for more than 48 hours or weaned from mechanical ventilation within the previous 48 hours, had a new or progressing infiltrate on chest radiograph and who met at least two of the following clinical criteria: body temperature >38°C or <36°C with no other recognised cause, white blood cell count >10,000 /mm 3 or <5000 /mm 3 , or a macroscopically purulent tracheal aspirate. Only the first VAP episode was included and only those patients who had a pathogen defined at baseline were evaluated as this represented a similar population to that used in the original study. VAP episodes were classified as early or late onset according to criteria established by the American Thoracic Society and the Infectious Diseases Society of America 1 .
Variables
Patient demographics as well as clinical and microbiological data were recorded to calculate the APACHE II score within 24 hours of ICU admission and VAP PIRO score and VAP APACHE II score on day of VAP identification. As described by Lisboa and colleagues in the original presentation of VAP PIRO, mortality at the end of ICU stay was used as the primary endpoint 9 . Mortality at 28 days after the VAP diagnosis date was also evaluated as this is a common endpoint used in VAP outcomes research.
Definitions
All co-morbidity definitions were followed as described by the original validation study 9 . Briefly, chronic obstructive pulmonary disease was defined as the presence of chronic bronchitis and emphysema. Immunocompromised was defined as immunodeficiency primary or secondary to radiation, use of cytotoxic drugs or steroids (daily dose greater than 20 mg of prednisolone or equivalent for >2 weeks), cancer or AIDS. Chronic heart failure was defined by patients classified as having New York Heart Association class III or IV heart failure on admission. Chronic liver disease was considered in patients with documented cirrhosis, portal hypertension, previous upper gastrointestinal bleeding secondary to portal hypertension, or encephalopathy. Chronic renal failure was defined in patients who were undergoing long-term haemodialysis. Bacteraemic episodes of VAP were defined as isolation of at least one positive blood culture not related to another source of infection, matching at least one positive respiratory sample obtained within 48 hours. At least one of the respiratory micro-organisms had to be isolated in blood cultures and all isolated micro-organisms were required to grow in simultaneous respiratory samples. Hypotension was defined as the presence of systolic blood pressure <90 mmHg within 24 hours of VAP diagnosis or need of vasopressor drugs to maintain the blood pressure above this value. Acute respiratory distress syndrome was defined according to the American-European Consensus Conference Committee criteria 12 . We defined patients as a head injury if they were admitted to the neurotrauma ICU with stroke, brain anoxia or as a result of a motor vehicle accident or other trauma to the head.
Statistical analysis
Data were analysed using SigmaStat Version 2 (SYSTAT Software Inc, Chicago, IL, USA) software and area under the receiver operating characteristic (AUROC) curves were constructed by MedCalc Version 11 (MedCalc Software, Belgium). Continuous variables were analysed by Student's t-test or Mann-Whitney rank sum test as appropriate. Categorical variables were compared with chi-square and Fisher exact test as appropriate. Sensitivity, specificity, positive predictive value and negative predictive value for predicting ICU mortality and 28-day mortality for APACHE II, VAP APACHE II and VAP PIRO scores were determined. AUROC and 95% confidence intervals (CI) were compared between scores. To explore which baseline characteristics were predictive of ICU mortality in our independent population, logistic regression was performed utilising all variables with a P value <0.2 during univariate analyses. An a priori P value <0.05 was considered significant for all final analyses.
RESULTS
One hundred and sixty-eight VAP patients were evaluated and 20 were excluded because no baseline pathogen could be identified, leaving 148 patients for evaluation in the study. The baseline characteristics of patients stratified by survival to ICU discharge are displayed in Table 1 . Overall ICU mortality was 25% and 28-day mortality was 25.7%. Survivors and non-survivors had median post-VAP ICU stays of 17 days (range 3 to 80) and 10 days (range 1 to 91), respectively. Causative pathogens are provided in Table 2 . Staphylococcus aureus (28.3%) was the most prevalent pathogen followed by Pseudomonas aeruginosa (27.7%) and Klebsiella pneumoniae (16.2%). The majority of pathogens were identified by tracheal aspirates (86.4%). Eight percent of patients had baseline pathogens indentified by bronchoalveolar lavage.
Most patients in this cohort had a mild to high PIRO score (0 to 1 and 2, respectively). Only 9 (6%) of the patients had a VAP PIRO score >2 and none of these patients met all four criteria identified by Lisboa and colleagues. The median (range) VAP PIRO score for non-survivors and survivors were 2 (0 to 3) and 1 (0 to 3), respectively, P=0.057. ICU mortality by PIRO score and corresponding APACHE II and VAP APACHE II ranges are provided in Figure 1 .
ICU mortality gradually increased from 15.2% for patients with a PIRO score of 0 to 44.4% for a PIRO score of 3. Using increments of five points after an APACHE II and VAP APACHE II of 15, ICU mortality also gradually increased with increasing APACHE II and VAP APACHE II ranges. A VAP PIRO score threshold ≥2 had the most consistent sensitivity and specificity, but these values were 57 and 59% respectively for ICU mortality, and 53 and 58% respectively for 28-day mortality ( Table 3) .
The AUROC for the VAP PIRO score (AUROC 0.605; 95% CI 0.521 to 0.684, P=0.03) was similar to APACHE II score (AUROC 0.631; 95% CI 0.548 to 0.709, P=0.01) for predicting ICU mortality (P value for difference between areas, P=0.68) (Figure 2) .
The AUROC for the VAP APACHE II score (AUROC 0.724; 95% CI 0.645 to 0.795, P <0.0001) was also similar to both APACHE II AUROC (P=0.15) and VAP PIRO AUROC (P=0.054). The AUROC of the scores were also similar when assessing 28-day mortality as the endpoint. The VAP PIRO AUROC was 0.614 (95% CI 0.530 to 0.692, P=0.01), the APACHE II was 0.633 (95% CI 0.550 to 0.710, P=0.01) and the VAP APACHE II was 0.697 (95% CI 0.616 to 0.770, P=0.0002). Again, no differences between areas were observed (APACHE II vs VAP PIRO, P=0.77; APACHE II vs VAP APACHE II, P=0.35; and VAP PIRO vs VAP APACHE II, P=0.22).
On multivariate logistic regression, only APACHE II score and presence of bacteraemic pneumonia were independently associated with ICU-mortality ( Table 4 ).
The VAP PIRO score was not independently predictive of ICU mortality when assessed with or without APACHE II or VAP APACHE II scores in the model. In addition, by utilising VAP APACHE II instead of APACHE II, the same variables persisted in the model with bacteraemia with odds ratio 8.88, 95% CI 1.30 to 60.58, P=0.02 and VAP APACHE II with odds ratio 1.16, 95% CI 1.08 to 1.25, P <0.0001. 
DISCUSSION
The present study sought to evaluate the ability of the VAP PIRO score to predict ICU and 28-day mortality, as this score has not been validated in an independent population of VAP patients. Our findings did not confirm the robust performance observed previously with the VAP PIRO score for predicting ICU mortality 9 . In our population of VAP patients, the VAP PIRO score and APACHE II score were outperformed by VAP APACHE II score in their ability to predict ICU mortality and 28-day mortality. In addition, VAP PIRO score was not a significant predictor of ICU mortality on multiple logistic regression analysis, whereas both APACHE II and VAP APACHE II were.
The VAP PIRO score was developed in a population of 441 patients with a diagnosis of VAP based on clinical criteria in addition to quantitative cultures of tracheal aspirates or bronchoalveolar lavage 9 . VAP PIRO demonstrated consistent mortality discrimination among subgroups of trauma versus non-trauma, medical versus surgical and early-versus late-onset VAP populations: furthermore, it outperformed the APACHE II score as demonstrated by AUROCs of 0.81 vs 0.53 (P <0.001), respectively. However, among our population of 148 culture positive VAP patients, AUROCs for predicting ICU mortality were similar for VAP PIRO and APACHE II (0.605 vs 0.631, P=0.68). Although mortality trended upwards with increasing VAP PIRO score (Figure 1) , the sensitivity and specificity for a score threshold ≥2 were only 57% and 59% in our population, values much lower than the 79.8% sensitivity and 73.4% specificity for this threshold reported in the derivation population.
The reasons for the observed differences between the two studies may be severalfold. First, Lisboa's population was defined in part by quantitative cultures of tracheal aspirates (96% of patients) and bronchoalveolar lavage fluid (4% of patients). Although recommended by the American Thoracic Society/Infectious Diseases Society of America guidelines for the microbiological definition of VAP 1 , quantitative cultures are not considered by many to impart greater diagnostic sensitivity compared with qualitative tracheal aspirates 13 . The randomised study in 740 patients with suspected VAP conducted by the Canadian Critical Care Trials Group found no difference in mortality between patients who received quantitative bronchoalveolar lavage versus endotracheal aspirates without quantitation 14 . Quantitative cultures were not routinely conducted at our hospital at the time of this study; however, all included patients had qualitative cultures conducted by endotracheal aspiration or bronchoalveolar lavage. Of note, when VAP PIRO and APACHE II were analysed for our entire 168 patient population (including the 20 patients who were culture negative), APACHE II remained a significant predictor of ICU-and 28-day mortality (data not shown). Second, given the variation in critical illness and underlying co-morbidites among ICU patients, it would not be surprising that the VAP populations may have been different. Lastly, antibiotic therapy was not well described in the original study. Any of these variables may have greatly affected overall mortality, which was numerically higher in their population (37%) compared with ours (25%). Potential differences among VAP patients across hospitals and continents makes complete validation of the VAP PIRO score in an independent population even more important, since clinicians and researchers who will apply the score are unlikely to pay significant attention to these minor details.
Currently, there is a scarcity of scores for predicting mortality in VAP patients. VAP PIRO is an attractive mortality predictor mainly due to its simplicity as compared with other more cumbersome scores. Although APACHE II is often utilised, it has demonstrated problems with reproducibility in some cases 15 . Conversely, in a recent study, the APACHE II score defined on the day of diagnosis of VAP (VAP APACHE II) was predictive of patient mortality with an AUROC of 0.81 6 . Another recent new score for predicting mortality in patients with VAP, IBMP-10, was introduced and demonstrated an AUROC of 0.824 for predicting 14-day mortality 7 . Nonetheless, this score was completely validated in the original report and data from the same population utilised herein found IBMP-10 to be less predictive than APACHE II 16 . Two recent studies have analysed the concept of PIRO in predicting in-hospital mortality in patients with sepsis 17, 18 . In these studies, PIRO presented AUROCs between 0.69 and 0.77. However, the components of the PIRO score in these studies were rather different from the ones used to predict mortality in VAP patients.
Additionally, we performed multiple logistic regression to see independent predictors of ICU mortality in our population. Interestingly, only bacteraemia and APACHE II or VAP APACHE II scores were found as independent variables associated with ICU mortality in our cohort, including or not including VAP PIRO in the analysis. In a recent study, APACHE II score >16 was also an independent predictor of mortality. Moreover, in that study, APACHE II score had a high AUROC (0.81) 6 . Differently from the original study where comorbidities were found as predictors of ICU mortality, the sole VAP PIRO component found as significant in our study was bacteraemia. This variable was also previously found as a predictor of mortality in two recent studies with VAP patients 19, 20 . The importance of this observation is severalfold.
Our study has limitations. First, as a singlecenter retrospective analysis our data might not be generalised to all settings. Second, in our cohort no patient had a VAP PIRO score of 4 and only nine patients had a score of 3. Indeed, our relatively low number of patients might have affected the results of the study.
In conclusion, our study demonstrated that APACHE II was the sole score that independently predicted mortality for an independent population of culture positive VAP patients. VAP PIRO score was not a good predictor of ICU-and 28-day mortality. Its low sensitivity and specificity of VAP PIRO score preclude its use clinically as a predictor of ICU mortality.
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